로그인|회원가입|고객센터|기업교육 문의
페이지 맨 위로 이동
검색

Clinical Trial

SK Biopharm Files for FDA Nod After 71.9% Seizure Drop

Dong-A Ilbo | Updated 2026.11.04
 
SK Biopharm announced on the 4th that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the treatment indications for its novel epilepsy drug cenobamate (U.S. product name Xcopri).

According to SK Biopharm, on the 3rd (local time) the company filed an application with the FDA to expand the indication to the treatment of primary generalized tonic-clonic seizures (PGTC) in patients aged 12 years and older. This is a procedure to broaden cenobamate’s treatment scope from mainly focal-onset seizures to generalized seizures.

PGTC is a type of epileptic seizure that begins in both hemispheres of the brain and is characterized by loss of consciousness, generalized muscle stiffness, and repetitive convulsions. Cenobamate is currently approved and used in the United States as a treatment for focal-onset seizures in adults.

This application is based on the results of a global Phase 3 clinical trial announced in September last year. The trial was conducted on 169 PGTC patients aged 12 years and older at 122 medical institutions in 12 countries, including the United States, Korea, and several European nations.

In the clinical trial, patients treated with cenobamate showed a 71.9% reduction in seizure frequency compared with baseline. By contrast, the placebo group, which received a sham treatment, recorded a 39.6% reduction. These figures represent the median percentage reduction in seizure frequency for each group, and a greater reduction was observed in the cenobamate group; the difference between the two groups was also statistically significant.

In the safety assessment, most reported adverse events were mild to moderate in severity and were consistent with the previously known safety profile, SK Biopharm explained. No new safety concerns were observed, it added.

SK Biopharm expects that, if it obtains additional approval from the FDA, it will be able to expand the treatment population for cenobamate from adults with focal-onset seizures to patients aged 12 years and older with PGTC.

The company also submitted another sNDA to the FDA in October to extend the existing adult focal-onset seizure indication to pediatric patients. Earlier in March, it had filed an NDA for an oral suspension formulation developed to improve dosing convenience for patients who have difficulty swallowing tablets.

SK Biopharm plans to broaden both the treatment population and prescribing options for cenobamate by adding new indications, expanding to younger age groups, and diversifying formulations. The company anticipates that, if it secures all three approvals, patients will be able to choose between tablets and an oral suspension according to their condition, thereby improving dosing convenience.

Cenobamate is an epilepsy drug independently developed by SK Biopharm and launched in the U.S. market in 2020. The company is pursuing a lifecycle management strategy to extend its treatment coverage from the current adult focal-onset seizure indication to other seizure types and pediatric patients.

Lee Dong-hoon, CEO of SK Biopharm, said, “This application to add the PGTC indication is an important turning point for broadening cenobamate’s treatment population and extending the product’s growth trajectory over the long term,” adding, “Through a lifecycle management strategy that encompasses indications, age groups, and formulations, we will provide more patients with treatment options and enhance our global competitiveness.”

Hwang So-young

AI-translated with ChatGPT. Provided as is; original Korean text prevails.
Popular News

경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.

Click!